Cargando…

Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer

SIMPLE SUMMARY: Early esophageal cancer is diagnosed in the context of reflux disease, surveillance of Barrett’s metaplasia, or during upper gastrointestinal endoscopy for other indications. High definition and virtual or dye chromoendoscopy are mandatory for the screening and evaluation of neoplasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumoulin, Franz Ludwig, Hildenbrand, Ralf, Oyama, Tsuneo, Steinbrück, Ingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916931/
https://www.ncbi.nlm.nih.gov/pubmed/33670208
http://dx.doi.org/10.3390/cancers13040752
_version_ 1783657590042918912
author Dumoulin, Franz Ludwig
Hildenbrand, Ralf
Oyama, Tsuneo
Steinbrück, Ingo
author_facet Dumoulin, Franz Ludwig
Hildenbrand, Ralf
Oyama, Tsuneo
Steinbrück, Ingo
author_sort Dumoulin, Franz Ludwig
collection PubMed
description SIMPLE SUMMARY: Early esophageal cancer is diagnosed in the context of reflux disease, surveillance of Barrett’s metaplasia, or during upper gastrointestinal endoscopy for other indications. High definition and virtual or dye chromoendoscopy are mandatory for the screening and evaluation of neoplasia. Endoscopic treatment options include endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). Resection is considered curative if histopathology confirms low or absent risk of lymph node metastasis. Barrett’s high-grade dysplasia or early adenocarcinoma is treated by EMR or ESD, followed by ablation of Barrett’s epithelium to avoid metachronous cancer. ESD is the treatment of choice for squamous cell neoplasia. Excellent outcomes have been reported if the ESD of squamous cell cancer with slight submucosal infiltration and thus substantial risk for lymph node metastasis was combined with adjuvant chemo-radiotherapy. In contrast, infiltration of squamous cell cancer exceeding the lamina propria mucosae is not curative. However, despite a substantial risk of lymph node metastasis, excellent outcomes have recently been reported if endoscopic resection of tumors with up to 200 µm submucosal infiltration was combined with adjuvant chemo-radiotherapy. ABSTRACT: Diagnosis of esophageal adenocarcinoma mostly occurs in the context of reflux disease or surveillance of Barrett’s metaplasia. Optimal detection rates are obtained with high definition and virtual or dye chromoendoscopy. Smaller lesions can be treated with endoscopic mucosal resection. Endoscopic submucosal dissection (ESD) is an option for larger lesions. Endoscopic resection is considered curative (i.e., without significant risk of lymph node metastasis) if histopathology confirms en bloc and R0 resection of a well-differentiated (G1/2) tumor without infiltration of lymphatic or blood vessels and the maximal submucosal infiltration depth is 500µm. Ablation of remaining Barrett’s metaplasia is important, to reduce the risk of metachronous cancer. Esophageal squamous cell cancer is associated with different risk factors, and most of the detected lesions are diagnosed during upper gastrointestinal endoscopy for other indications. Virtual high definition and dye chromoendoscopy with Lugol’s solution are used for screening and evaluation. ESD is the preferred resection technique. The criteria for curative resection are similar to Barrett’s cancer, but the maximum infiltration depth must not exceed lamina propria mucosae. Although a submucosal infiltration depth of up to 200 µm carries a substantial risk of lymph node metastasis, ESD combined with adjuvant chemo-radiotherapy gives excellent results. The complication rates of endoscopic resection are low, and the functional outcomes are favorable compared to surgery.
format Online
Article
Text
id pubmed-7916931
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79169312021-03-01 Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer Dumoulin, Franz Ludwig Hildenbrand, Ralf Oyama, Tsuneo Steinbrück, Ingo Cancers (Basel) Commentary SIMPLE SUMMARY: Early esophageal cancer is diagnosed in the context of reflux disease, surveillance of Barrett’s metaplasia, or during upper gastrointestinal endoscopy for other indications. High definition and virtual or dye chromoendoscopy are mandatory for the screening and evaluation of neoplasia. Endoscopic treatment options include endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). Resection is considered curative if histopathology confirms low or absent risk of lymph node metastasis. Barrett’s high-grade dysplasia or early adenocarcinoma is treated by EMR or ESD, followed by ablation of Barrett’s epithelium to avoid metachronous cancer. ESD is the treatment of choice for squamous cell neoplasia. Excellent outcomes have been reported if the ESD of squamous cell cancer with slight submucosal infiltration and thus substantial risk for lymph node metastasis was combined with adjuvant chemo-radiotherapy. In contrast, infiltration of squamous cell cancer exceeding the lamina propria mucosae is not curative. However, despite a substantial risk of lymph node metastasis, excellent outcomes have recently been reported if endoscopic resection of tumors with up to 200 µm submucosal infiltration was combined with adjuvant chemo-radiotherapy. ABSTRACT: Diagnosis of esophageal adenocarcinoma mostly occurs in the context of reflux disease or surveillance of Barrett’s metaplasia. Optimal detection rates are obtained with high definition and virtual or dye chromoendoscopy. Smaller lesions can be treated with endoscopic mucosal resection. Endoscopic submucosal dissection (ESD) is an option for larger lesions. Endoscopic resection is considered curative (i.e., without significant risk of lymph node metastasis) if histopathology confirms en bloc and R0 resection of a well-differentiated (G1/2) tumor without infiltration of lymphatic or blood vessels and the maximal submucosal infiltration depth is 500µm. Ablation of remaining Barrett’s metaplasia is important, to reduce the risk of metachronous cancer. Esophageal squamous cell cancer is associated with different risk factors, and most of the detected lesions are diagnosed during upper gastrointestinal endoscopy for other indications. Virtual high definition and dye chromoendoscopy with Lugol’s solution are used for screening and evaluation. ESD is the preferred resection technique. The criteria for curative resection are similar to Barrett’s cancer, but the maximum infiltration depth must not exceed lamina propria mucosae. Although a submucosal infiltration depth of up to 200 µm carries a substantial risk of lymph node metastasis, ESD combined with adjuvant chemo-radiotherapy gives excellent results. The complication rates of endoscopic resection are low, and the functional outcomes are favorable compared to surgery. MDPI 2021-02-11 /pmc/articles/PMC7916931/ /pubmed/33670208 http://dx.doi.org/10.3390/cancers13040752 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Dumoulin, Franz Ludwig
Hildenbrand, Ralf
Oyama, Tsuneo
Steinbrück, Ingo
Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title_full Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title_fullStr Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title_full_unstemmed Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title_short Current Trends in Endoscopic Diagnosis and Treatment of Early Esophageal Cancer
title_sort current trends in endoscopic diagnosis and treatment of early esophageal cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916931/
https://www.ncbi.nlm.nih.gov/pubmed/33670208
http://dx.doi.org/10.3390/cancers13040752
work_keys_str_mv AT dumoulinfranzludwig currenttrendsinendoscopicdiagnosisandtreatmentofearlyesophagealcancer
AT hildenbrandralf currenttrendsinendoscopicdiagnosisandtreatmentofearlyesophagealcancer
AT oyamatsuneo currenttrendsinendoscopicdiagnosisandtreatmentofearlyesophagealcancer
AT steinbruckingo currenttrendsinendoscopicdiagnosisandtreatmentofearlyesophagealcancer